Company News
Georgia Research Alliance Trustees Name New President and CEO
Tim Denning, Ph.D. will succeed retiring Susan Shows in November The Trustees of the Georgia Research Alliance voted today to appoint Timothy Denning, Ph.D., vice president for research and economic development at Georgia State University, as the fifth president and CEO of GRA. He will take the reins from Susan Shows, who announced her retirement in a…
Read MoreLucid Scientific Secures $7 Million Series A Financing Led by IAG Capital Partners
Maker of continuous real-time metabolic analysis systems experiences growing demand. Will build capacity for new product offerings, manufacturing, and global sales and marketing. September 26, 2023 05:42 PM Eastern Daylight Time ATLANTA–(BUSINESS WIRE)–Lucid Scientific, a life science instruments company that manufactures Resipher, announced the completion of a $7 million Series A financing led by IAG…
Read MoreSaol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial
SL-1002 is currently being developed for the treatment of chronic knee pain associated with osteoarthritis (COMPASS Trial) and mild to severe limb spasticity (RAISE Trial). Topline data for the COMPASS Osteoarthritis Knee Pain Trial will be available in the first quarter of 2024, with topline data from the RAISE Limb Spasticity Trial available shortly thereafter. …
Read MoreDanish manufacturing firm breaks ground in Peachtree City; 200 new jobs expected
By The Citizen-August 22, 2023 SP Meditec recently broke ground on a 120,000 square foot, state-of-the-art manufacturing facility that is expected to create 200 new jobs in Peachtree City. The plant, which will be located off Georgia State Route 74, is scheduled to begin operations in August 2024. Several factors played into SP Meditec’s selection…
Read MoreGeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, September 11, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has met the enrollment target for its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster for healthy patients…
Read MoreSanguina Raises $2.8M in Series A Funding to Drive Innovation in Home-Based Testing and Wellness Management
PEACHTREE CORNERS, Ga.–(BUSINESS WIRE)–Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its $2.8m Series A funding round. Led by Veritus Holdings, the round saw participation from notable investors, including George Hornig of The Seed Lab and Stephen Ippolito of Veritus Holdings. The funding will be…
Read MoreGeoVax Announces Issuance of Ebola Vaccine Patent
Addressing Multiple Strains of Ebolavirus Atlanta, GA, July 24, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,701,418 B2 to GeoVax, pursuant to the Company’s patent application No. 15/543,139 titled “Replication-Deficient…
Read MoreGeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA, July 20, 2023 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the start of an investigator-initiated clinical trial (ClinicalTrials.gov Identifier: NCT05672355), titled “Randomized observer-blinded phase 2 trial of COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech…
Read MoreOncoLens Welcomes Cross Border Impact Venture Fund as Capital Partner to Fuel International Growth
ATLANTA (PRWEB) JULY 13, 2023 OncoLens provides an integration and collaboration platform to cancer centers, helping derive intelligence from swaths of disparate structured and unstructured data to empower centers to identify patients for clinical trials, research, biomarker testing and more. Insights derived are funneled into collaboration workflows and matched with clinical decision support to assist often siloed…
Read MoreControl Dialysis Cannulation Pain – New Buzzy Pro Receives FDA 510K Indication
Dialysis cannulation pain impacts half a million patients. Proven Buzzy device is now FDA indicated to control dialysis, blood donation & lab draw needle pain. ATLANTA, GEORGIA, U.S., July 12, 2023/EINPresswire.com/ — Dialysis patients can now get more pain relief during treatment thanks to Buzzy’s recently expanded FDA indications. Pain Care Labs has received augmented…
Read More